Liso-Cel/Breyanzi Approved for Relapsed/Refractory Mantle Cell Lymphoma
This is a developing story and will be updated with new information as it becomes available. The FDA has approved Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel, marketed as Breyanzi), an autologous CD19-directed chimeric antigen receptor (CAR) …